Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max Kates

Showing results (111-120 of 157) with videos related to

Pageof 16
Sort By:
The Journal of Sexual Medicine|February 6, 2017
M1 Macrophages Are Predominantly Recruited to the Major Pelvic Ganglion of the Rat Following Cavernous Nerve InjuryHotaka Matsui, Nikolai A Sopko, Johanna L Hannan, et al.
Urologic Oncology|January 20, 2022
Residual CIS after neoadjuvant chemotherapy and radical cystectomy for muscle invasive bladder cancer: Implications for neoadjuvant trialsAndrew T Gabrielson, Marcus J Daniels, Julian Rowe, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|August 29, 2020
Urothelial Carcinoma In Situ of the Bladder: Correlation of CK20 Expression With Adaptive Immune Resistance, Response to BCG Therapy, and Clinical OutcomeKara A Lombardo, Belkiss Murati Amador, Vamsi Parimi, et al.
Urologic Oncology|September 19, 2016
Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?Aaron Brant, Max Kates, Meera R Chappidi, et al.
Drug Delivery and Translational Research|November 9, 2020
Preclinical evaluation of a hypotonic docetaxel nanosuspension formulation for intravesical treatment of non-muscle-invasive bladder cancerAbhijit A Date, Max Kates, Takahiro Yoshida, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|April 26, 2021
Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial HistotypesJean H Hoffman-Censits, Kara A Lombardo, Vamsi Parimi, et al.
Histopathology|February 8, 2023
Comparison of clinicopathological characteristics, gene expression profiles, mutational analysis, and clinical outcomes of pure and mixed small-cell carcinoma of the bladderVamsi Parimi, Woonyoung Choi, Mingxiao Feng, et al.
European Urology|September 29, 2023
Reply to Kentaro Inamura's Letter to the Editor re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al.
Urologic Oncology|August 21, 2025
Molecular classification of nonurothelial histologic subtypes of bladder cancerMichelle I Higgins, Andrew T Gabrielson, Zhuo Tony Su, et al.
The Journal of Urology|October 24, 2024
Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION)Sandip M Prasad, Dimitar Shishkov, Nikola Vladimirov Mihaylov, et al.
Pageof 16

Showing results (111-120 of 157) with videos related to

Sort By:
Pageof 16
The Journal of Sexual Medicine|February 6, 2017
M1 Macrophages Are Predominantly Recruited to the Major Pelvic Ganglion of the Rat Following Cavernous Nerve InjuryHotaka Matsui, Nikolai A Sopko, Johanna L Hannan, et al.
Urologic Oncology|January 20, 2022
Residual CIS after neoadjuvant chemotherapy and radical cystectomy for muscle invasive bladder cancer: Implications for neoadjuvant trialsAndrew T Gabrielson, Marcus J Daniels, Julian Rowe, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|August 29, 2020
Urothelial Carcinoma In Situ of the Bladder: Correlation of CK20 Expression With Adaptive Immune Resistance, Response to BCG Therapy, and Clinical OutcomeKara A Lombardo, Belkiss Murati Amador, Vamsi Parimi, et al.
Urologic Oncology|September 19, 2016
Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?Aaron Brant, Max Kates, Meera R Chappidi, et al.
Drug Delivery and Translational Research|November 9, 2020
Preclinical evaluation of a hypotonic docetaxel nanosuspension formulation for intravesical treatment of non-muscle-invasive bladder cancerAbhijit A Date, Max Kates, Takahiro Yoshida, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|April 26, 2021
Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial HistotypesJean H Hoffman-Censits, Kara A Lombardo, Vamsi Parimi, et al.
Histopathology|February 8, 2023
Comparison of clinicopathological characteristics, gene expression profiles, mutational analysis, and clinical outcomes of pure and mixed small-cell carcinoma of the bladderVamsi Parimi, Woonyoung Choi, Mingxiao Feng, et al.
European Urology|September 29, 2023
Reply to Kentaro Inamura's Letter to the Editor re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al.
Urologic Oncology|August 21, 2025
Molecular classification of nonurothelial histologic subtypes of bladder cancerMichelle I Higgins, Andrew T Gabrielson, Zhuo Tony Su, et al.
The Journal of Urology|October 24, 2024
Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION)Sandip M Prasad, Dimitar Shishkov, Nikola Vladimirov Mihaylov, et al.
Pageof 16